Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Everyone has their own rules for Super Bowl squares, but here at For The Win we’ve put together an easy-to-read — and printable! — template for you and your party to enjoy. Gambling involves ...

Anna Sui turned her eye to the world of the "madcap heiress" from the 1930s, a woman who the society pages of the time would ...

Cohen was inspired by the juxtaposition of ladylike glamour, a la Elizabeth Taylor, and sportif nods, a la Muhammad Ali.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...